PGT-A testing in IVF laboratory with embryologist examining embryos under a microscope
PGT-A testing in IVF: an embryologist examines embryos in the laboratory before transfer.

PGT-A Testing in IVF: What It Is, How It Works & Whether It’s Worth It

By Emily Johnson, Content Writer and Fertility Advocate. Medically reviewed by Dr. Sarah Ahmed, Medical Content Advisor.

If you are going through IVF, you have probably heard the term PGT-A testing, and probably heard two very different stories about it. Some clinics present it as a routine step that helps you pick the healthiest embryo. Others warn it is an expensive add-on with uncertain benefits. The truth sits between those two stories, and it depends a lot on your age, your history, and how many embryos you have.

Here is the short answer first: PGT-A testing in IVF is a screening test that checks whether an embryo has the expected number of chromosomes before it is transferred. A few cells are removed from a day 5 or 6 embryo, analyzed in a genetics laboratory, and the embryo is frozen while you wait for results, usually two to four weeks. Embryos with the expected chromosome number (called euploid) are prioritized for transfer. PGT-A can reduce the chance of miscarriage per transfer and shorten the time to pregnancy for some patients, but it does not guarantee a baby, it adds significant cost, and the evidence on whether it improves your overall chance of having a baby from a full IVF cycle is still unclear. This guide explains how it works, who it genuinely helps, what it costs, and the questions worth asking your clinic before you decide.

What Is PGT-A Testing?

PGT-A stands for preimplantation genetic testing for aneuploidy. Preimplantation means it happens before an embryo is placed in the uterus. Aneuploidy means having too many or too few chromosomes. PGT-A used to be called PGS (preimplantation genetic screening), the same idea, with a newer name and more accurate technology.

Every cell in a typical human embryo should contain 46 chromosomes, arranged in 23 pairs, one set from each parent. When an embryo has the expected number, it is called euploid. When it has an extra or missing chromosome, it is called aneuploid. Aneuploid embryos are much less likely to implant, and when they do implant they are more likely to miscarry or, in a small number of cases, lead to a baby with a chromosome condition. Down syndrome (trisomy 21, an extra copy of chromosome 21) is the best-known example.

The key point patients often miss: an embryo can look perfect under the microscope and still be aneuploid. That is exactly the gap PGT-A is designed to close. Embryo grading, the visual scoring your embryologist does, judges appearance, not chromosomes. PGT-A adds a different kind of information: the chromosome count.

PGT-A is a screening test, not a diagnosis. It looks at a handful of cells from the embryo’s outer layer, not the whole embryo, and like all screening tests it has limits, including a grey zone called mosaicism, covered below.

How PGT-A Testing Works, Step by Step

PGT-A fits into a standard IVF cycle without changing the first half of it. Stimulation, egg retrieval and fertilization all happen exactly as they normally would. The testing steps begin once your embryos reach the blastocyst stage.

Blastocyst embryo biopsy for PGT-A testing in IVF under a microscope
A blastocyst-stage embryo is biopsied for PGT-A testing in IVF.

1. Embryos grow to day 5 or 6

After fertilization, embryos develop in the laboratory for five to six days until they reach the blastocyst stage, a hollow ball of roughly 70 to 150 cells. Only embryos that reach this stage can be biopsied for PGT-A.

2. A few cells are biopsied

An embryologist uses a fine needle to remove a small sample, typically 3 to 10 cells, from the trophectoderm, the outer layer of the blastocyst that will go on to form the placenta. The inner cell mass, which becomes the baby, is not touched. The biopsy is done with a laser-assisted technique in experienced laboratories, and the risk of damage to the embryo is low, though not zero.

3. Embryos are frozen while results are processed

Because genetic analysis takes time, every biopsied embryo is frozen (vitrified) while the samples are sent to a specialist genetics laboratory. This is why PGT-A always means a frozen embryo transfer later, never a fresh transfer in the same cycle. If you are planning a frozen transfer, our FET calendar calculator can map your beta test, first ultrasound and milestone dates from your transfer day.

4. The laboratory counts the chromosomes

The laboratory uses next-generation sequencing (NGS) to examine the number of chromosomes in the biopsied cells. Each embryo is classified as euploid, aneuploid, or mosaic (a mix of normal and abnormal cells, see below). A small number come back as no result when the sample is insufficient, in which case the embryo can sometimes be re-biopsied after thawing.

5. Results arrive in two to four weeks

Turnaround varies by laboratory and clinic, but two to four weeks is typical. Your clinic will then discuss which embryos are suitable for transfer and in what order. Euploid embryos are transferred first; aneuploid embryos are generally not transferred; mosaic embryos sit in a middle category that needs a careful, individualized discussion.

Understanding Your PGT-A Results

Euploid: the expected chromosome number

A euploid embryo has 46 chromosomes. These embryos have the highest chance of implantation per transfer and the lowest miscarriage risk. Highest is not certain, even a euploid embryo does not guarantee pregnancy, because implantation also depends on the uterus, timing, and factors no test can measure.

Aneuploid: an extra or missing chromosome

An aneuploid embryo has too many or too few chromosomes, a whole extra chromosome (a trisomy), a missing chromosome (a monosomy), or sometimes a duplicated or deleted segment of a chromosome. Most aneuploid embryos either fail to implant or miscarry early. Clinics generally do not transfer aneuploid embryos, though the decision is ultimately made with your doctor and, where relevant, a genetic counsellor.

Mosaic: a mix of normal and abnormal cells

A mosaic embryo contains both chromosomally normal and abnormal cells in the biopsied sample. Mosaicism is the hardest result to interpret, because the few cells sampled may not represent the whole embryo, and some mosaic embryos can still lead to healthy pregnancies, while others cannot. Whether a mosaic embryo is considered for transfer depends on which chromosome is involved, how much of the sample is abnormal, and your clinic’s policy. This is an area of genuine, ongoing debate in fertility medicine, and it deserves its own detailed discussion with your doctor rather than a yes-or-no rule.

No result

Occasionally the laboratory cannot produce a result from the sample. This does not mean the embryo is abnormal, it means the test could not be completed. Your clinic may offer re-biopsy, or you may choose to transfer the embryo without a result, weighing the same trade-offs as an untested embryo.

Who Should Consider PGT-A Testing?

PGT-A is an optional add-on, not a default part of IVF, and it is typically discussed for patients in one or more of these situations:

  • Age 35 and over, especially 38 and over (the chance of aneuploidy rises steadily with the age of the egg provider; see IVF success rates by age)
  • Recurrent miscarriage (two or more pregnancy losses)
  • Repeated implantation failure (several good-quality embryos transferred without pregnancy)
  • Severe male-factor infertility (evidence less settled)
  • A previous pregnancy or child with a chromosome condition

PGT-A is least useful when you have very few embryos reaching blastocyst stage. If you have only one or two embryos, testing may not change your decision, you would likely transfer them anyway, while still adding cost, a freeze cycle, and a small biopsy risk. Ask your clinic directly: If we test and find what we expect, will it actually change which embryo we transfer, or the order? If the honest answer is no, PGT-A may not be worth it for that cycle.

The Benefits of PGT-A Testing

  • Fewer transfers to reach a pregnancy (higher ongoing pregnancy rates per transfer with PGT-A)
  • Lower miscarriage risk per transfer (most early miscarriages are caused by chromosome errors)
  • Shorter time to pregnancy (fewer failed transfers and fewer miscarriages can mean reaching a healthy pregnancy sooner, even if the total number of babies from one egg retrieval ends up the same)
  • Fewer twin pregnancies (a single euploid embryo makes single embryo transfer more comfortable, see single vs double embryo transfer)

The Risks, Limits and Downsides

  • It does not improve your overall chance of a baby from one retrieval, at least, not proven (best current evidence reviews find it unclear whether PGT-A affects the overall chance of having a baby when all embryos from a cycle are counted)
  • Embryo biopsy carries a small risk (low, not zero)
  • Freezing and thawing loses some embryos (approximately 2 to 5 percent do not survive)
  • Mosaic results can discard viable embryos or create agonizing decisions
  • It adds significant cost (roughly $3,000 to $6,000 per cycle in the US)
  • It delays transfer (two to four weeks plus a frozen cycle)
  • It cannot detect everything (PGT-A counts chromosomes only, not single-gene disorders, which is PGT-M, nor structural rearrangements, PGT-SR)

Regulators have noticed the gap between marketing and evidence: the UK’s fertility regulator, the HFEA, rates PGT-A as a red add-on, meaning there is no good evidence it increases the chance of pregnancy overall.

PGT-A vs PGT-M vs PGT-SR: What Is the Difference?

TestWhat it checksWhen it is used
PGT-ANumber of chromosomes (aneuploidy)Age-related risk, recurrent miscarriage, repeated implantation failure
PGT-MA specific single-gene condition (monogenic)One or both parents carry a known gene mutation, such as cystic fibrosis or sickle cell disease
PGT-SRStructural rearrangements of chromosomesA parent carries a balanced translocation or inversion

If you carry a known genetic condition, PGT-M or PGT-SR, not PGT-A, is the relevant test, and it requires building a custom probe for your family’s mutation before the cycle begins. Your clinic or a genetic counsellor will tell you which test, if any, fits your situation.

How Much Does PGT-A Testing Cost?

Costs vary by country, clinic and laboratory, and by how many embryos are biopsied. As a planning range for the United States, expect roughly $3,000 to $6,000 per cycle in addition to standard IVF costs, covering the biopsy procedure and the laboratory analysis. Some clinics charge per embryo beyond a base number; others charge a flat fee. Ask for the full breakdown in writing: biopsy fee, laboratory fee, per-embryo charges, and whether re-biopsy or a second report costs extra. Also ask whether your insurance covers any part of it, most US plans treat PGT-A as an optional add-on and do not cover it, but exceptions exist, particularly after recurrent miscarriage.

Does PGT-A Testing Improve IVF Success Rates?

  • Per transfer: yes, on average (higher ongoing pregnancy rate, lower miscarriage rate than an untested embryo of similar appearance)
  • Per egg retrieval (cumulative): unclear (best evidence reviews cannot say PGT-A increases the total chance of a baby)
  • For younger patients with many good embryos: the advantage shrinks
  • For older patients or those with repeated failures: the advantage grows

The honest framing is this: PGT-A is a tool for choosing the order of transfers and reducing miscarriage risk per transfer. It is not a tool that creates healthy embryos, fixes egg quality, or guarantees a baby. Any clinic that promises otherwise is overselling it.

Questions to Ask Your Clinic Before Deciding

Fertility doctor discussing PGT-A testing in IVF results with a couple
A fertility doctor discusses PGT-A testing in IVF results with a couple.

For independent regulator guidance on PGT-A as a treatment add-on, the UK Human Fertilisation and Embryology Authority (HFEA) publishes its evidence ratings and safety information for PGT-A.

  • How many of my embryos would you expect to reach blastocyst stage, and would testing change which one we transfer first?
  • What is your laboratory’s no-result rate, and what happens if an embryo gets no result?
  • What is your policy on mosaic embryos, do you ever transfer them, and under what conditions?
  • What is the total cost, including per-embryo charges, and is any of it covered by my insurance?
  • If I have only one or two blastocysts, do you still recommend testing, and why?
  • Can I speak to a genetic counsellor about my results before deciding on a transfer?

The Bottom Line

PGT-A testing in IVF is a genuinely useful screening tool for the right patient: it identifies embryos with the expected chromosome number before transfer, which can mean fewer failed transfers, fewer miscarriages, and a shorter path to pregnancy. Its limits are equally real: it adds $3,000 to $6,000 per cycle, requires freezing all embryos, carries a small biopsy and freeze-thaw risk, and has not been proven to increase the total chance of a baby from one egg retrieval. For patients over 38, those with recurrent miscarriage, or those with repeated implantation failure, it is often worth a serious conversation. For younger patients with few embryos, it may add cost without changing the decision. The right question is never is PGT-A good or bad, it is will it change what we do in my cycle? Ask that, get a straight answer, and the decision usually makes itself.

Frequently Asked Questions (FAQs)

What does PGT-A testing check for?

PGT-A testing checks whether an IVF embryo has the expected number of chromosomes (46) before transfer. It screens for aneuploidy, extra or missing chromosomes, which is a leading cause of implantation failure and early miscarriage.

Does PGT-A testing harm the embryo?

The biopsy removes a few cells from the embryo’s outer layer (the trophectoderm), not from the cells that become the baby. In experienced laboratories the risk of damage is low, but it is not zero, and about 2 to 5 percent of embryos do not survive the freezing and thawing that PGT-A requires.

How long do PGT-A results take?

Results typically take two to four weeks from the biopsy. Because embryos must be frozen while results are processed, PGT-A always leads to a frozen embryo transfer in a later cycle, not a fresh transfer.

Can mosaic embryos be transferred?

Sometimes, depending on the clinic and the details of the result. A mosaic embryo has a mix of normal and abnormal cells in the sample, and some can lead to healthy pregnancies. Transfer decisions for mosaic embryos should be made with your doctor and, ideally, a genetic counsellor, policies vary widely between clinics.

Does PGT-A guarantee a pregnancy?

No. PGT-A improves the chance of success per transfer and reduces miscarriage risk per transfer, but even a euploid embryo does not guarantee implantation or a baby. It also has not been proven to increase the total chance of a baby from one full egg retrieval.

How much does PGT-A testing cost?

In the United States, PGT-A typically adds roughly $3,000 to $6,000 per IVF cycle, depending on the clinic, the the laboratory, and the number of embryos tested. Most insurance plans do not cover it, so confirm coverage and get the full fee breakdown in writing before deciding.

Who is PGT-A testing recommended for?

It is most often discussed for patients aged 35 and over (especially 38+), those with recurrent miscarriage, repeated implantation failure, or a previous pregnancy affected by a chromosome condition. It is least useful when you have only one or two embryos, since testing may not change which embryo is transferred.

What is the difference between PGT-A and PGS?

They are the same concept. PGS (preimplantation genetic screening) was the older name; PGT-A (preimplantation genetic testing for aneuploidy) is the current term, reflecting newer, more accurate sequencing technology. PGT-M and PGT-SR are different tests for single-gene conditions and structural rearrangements.

About the author: Emily Johnson is a Content Writer and Fertility Advocate who covers IVF and fertility treatment topics. Meet the team.

Medical review: This article was medically reviewed by Dr. Sarah Ahmed, Medical Content Advisor, for clinical accuracy. Meet the team.

Medical disclaimer: This article is for informational purposes only and is not medical advice, diagnosis, or treatment. Due dates are estimates, and every pregnancy is different. Always confirm your due date and any testing or treatment decisions with your clinic or healthcare provider.

One Comment

Leave a Reply

Your email address will not be published. Required fields are marked *